Download PDF
Klin Monbl Augenheilkd 2023; 240(04): 578-580
DOI: 10.1055/a-2004-5629
Der interessante Fall

Presumed Ocular Histoplasmosis Syndrome in a Five-Year-Old Girl in a Non-Endemic Area

Vermutetes okuläres Histoplasmose-Syndrom bei einem 5-jährigen Mädchen in einer nicht endemischen Zone
Nathalie Voide
Ophthalmology/Strabismus and Pediatric Ophthalmology Unit, Jules Gonin Eye Hospital, Lausanne, Switzerland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Background

Presumed ocular histoplasmosis syndrome (POHS) is a noninflammatory chorioretinal disorder with a distinct fundus appearance that consists of

  1. circumferential peripapillary atrophy (PPA), usually pigmented,

  2. bilateral mid-peripheral disseminated “punched-out” chorioretinal scars, called “histo spots”, and

  3. the possible development of secondary choroidal neovascularization (CNV) or corresponding sequelae such as disciform scars [1].

There is no consensus on its pathogenesis. POHS is commonly found in regions endemic to the inhalable dimorphic fungus Histoplasma capsulatum (HC), i.e., the Midwest and Southeast of the USA (Mississippi and Ohio River valley regions). Although histoplasmosis is the most endemic mycosis in the world, POHS has only been reported in a few countries outside the USA, such as Mexico, India, the United Kingdom, and the Netherlands. Its incidence is largely unknown, and males and females are equally affected [2].

The primary infection presumably occurs many years before the development of symptoms and the diagnosis is usually made during midlife when the disease becomes symptomatic due to macular CNV. POHS is therefore considered one of the principal causes of central vision loss among young adults in endemic areas, secondary to subfoveal CNVs, resulting in significant visual impairment (≤ 0.1 of visual acuity) [2], [3].



Publication History

Received: 16 October 2022

Accepted: 28 December 2022

Article published online:
25 April 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Freund BK, Sarraf D, Mieler WF. et al. The retinal atlas. 2nd ed.. ed. Amsterdam: Elsevier; 2016: 467-468
    Google Scholar
  • 2 Diaz RI, Sigler JS, Rafieetary MR. et al. Ocular histoplasmosis syndrome. Surv Ophthalmol 2015; 60: 279-295
    CrossrefPubMedGoogle Scholar
  • 3 Feman SS, Podgorski SF, Penn MK. Blindness from presumed ocular histoplasmosis in Tennessee. Ophthalmology 1982; 89: 1295-1298
    CrossrefPubMedGoogle Scholar
  • 4 Krause AC, Hopkins WG. Ocular manifestation of histoplasmosis. Am J Ophthalmol 1951; 34: 564-566
    CrossrefPubMedGoogle Scholar
  • 5 Smith RE, Dunn S, Jester JV. Natural history of experimental histoplasmic choroiditis in the primate. II. Histopathologic features. Invest Ophthalmol Vis Sci 1984; 25: 810-819
    PubMedGoogle Scholar
  • 6 Spencer WH, Chan CC, Shen DF. et al. Detection of histoplasma capsulatum DNA in lesions of chronic ocular histoplasmosis syndrome. Arch Ophthalmol 2003; 121: 1551-1555
    CrossrefPubMedGoogle Scholar
  • 7 Spaeth GL. Absence of so-called histoplasma uveitis in 134 cases of proven histoplasmosis. Arch Ophthalmol 1967; 77: 41-44
    CrossrefPubMedGoogle Scholar
  • 8 Bonifaz A, Vazquez-Gonzalez D, Perusquia-Ortiz AM. Endemic systemic mycosis: coccidioidomycosis, histoplasmosis, paracoccidioidomycosis and blastomycosis. J Dtsch Dermatol Ges 2011; 9: 705-714
    CrossrefPubMedGoogle Scholar
  • 9 Wilkes MF, Miller DM, Mitchell MD. et al. Investigation of choroidal neovascularization risk alleles in ocular histoplasmosis. Ophthalmology 2014; 121: 1487-1488.e1
    CrossrefPubMedGoogle Scholar
  • 10 Han DP, McAllister JT, Weinberg DV. et al. Combined intravitreal anti-VEGF and verteporfin photodynamic therapy for juxtafoveal and extrafoveal choroidal neovascularization as an alternative to laser photocoagulation. Eye (Lond) 2010; 24: 713-716
    CrossrefPubMedGoogle Scholar